FDA Funding Helped By Ebola Emergency Spending, But Opioid Issue Still Rankles Appropriators
This article was originally published in RPM Report
Executive Summary
Spending agreement includes $137 more for FDA—most from user fee increases previously enacted. Still, discretionary budget does go up for FDA, albeit at the cost of a rider demanding final action on abuse-deterrent formulation guidance by June.
You may also be interested in...
Seeking Guidance On Abuse-Deterrence: Sponsors Fall Short, Congress Urges Action
Congressional appropriators are urging FDA to move quickly to finalize guidance on abuse deterrence claims for opioids—and to take the next step and prohibit marketing of products that don’t deter abuse. FDA says the science isn’t there yet, and two sponsors join the list of those who have failed to clear the hurdle.
FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.